Biogen Inc. (BIIB)

Biogen Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	1,074	1,050	3,419	2,261	1,331	2,914
Short-Term Investments	0	0	1,474	1,541	1,279	1,562
Cash & Cash Equivalents	1,074	1,050	4,893	3,803	2,610	4,476
Cash Growth	-78.69%	-78.54%	28.67%	45.68%	-41.69%	26.51%
Receivables	2,000	2,100	2,136	1,962	2,327	2,471
Inventory	2,517	2,527	1,344	1,352	1,069	804.2
Other Current Assets	1,165	1,182	1,418	740.8	881.1	631
Total Current Assets	6,756	6,859	9,791	7,857	6,887	8,382
Property, Plant & Equipment	3,703	3,730	3,703	3,792	3,845	3,674
Long-Term Investments	697.6	745	2,235	2,832	3,671	2,661
Goodwill and Intangibles	14,512	14,582	7,599	7,982	8,846	9,285
Other Long-Term Assets	898.3	928.6	1,226	1,415	1,370	3,232
Total Long-Term Assets	19,811	19,986	14,763	16,021	17,732	18,853
Total Assets	26,568	26,845	24,554	23,877	24,619	27,234
Accounts Payable	387	403.3	491.5	589.2	454.9	530.8
Current Debt	250	150	0	999.1	0	1,496
Other Current Liabilities	2,586	2,881	2,781	2,710	3,287	2,837
Total Current Liabilities	3,223	3,434	3,273	4,298	3,742	4,864
Long-Term Debt	6,697	7,188	6,614	6,604	7,828	4,872
Other Long-Term Liabilities	1,435	1,423	1,279	2,015	2,362	4,160
Total Long-Term Liabilities	8,132	8,611	7,893	8,619	10,191	9,031
Total Liabilities	11,355	12,045	11,166	12,918	13,933	13,895
Total Debt	6,947	7,338	6,614	7,604	7,828	6,368
Debt Growth	5.10%	10.95%	-13.01%	-2.87%	22.94%	7.26%
Retained Earnings	18,021	17,628	16,467	13,912	13,976	16,455
Comprehensive Income	-160.5	-153.7	-164.9	-106.7	-299	-135.2
Shareholders' Equity	15,213	14,799	13,398	10,896	10,700	13,343
Net Cash / Debt	-5,872.2	-6,288.3	-1,721.2	-3,801	-5,218.1	-1,891.6
Net Cash Per Share	-40.25	-43.19	-11.79	-25.41	-32.35	-10.09
Working Capital	3,533	3,425	6,518	3,558	3,145	3,518
Book Value Per Share	104.77	102.28	92.21	73.08	66.50	71.32

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).